Report
Cosmin Filker ...
  • Julien Desrosiers

Research Comment - Defence Therapeutics Inc. - 24.01.22

Defence Therapeutics is a pre-clinical biotechnology company developing a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company's nextgeneration therapeutics target various tumors and infectious diseases. The company primary asset is the 100% owned proprietary platform ACCUMTM Technology. This molecule enhances drug delivery method and has various applications in oncology and vaccine development against infectious diseases. ACCUMTM was engineered in 2016 at the Université de Sherbrooke laboratories in Canada. The researchers were looking to find a way to improve radio imagery by increasing the amount of radioactive compound absorbed by a cell’s nucleus to get better imagery analysis. Defence Therapeutics acquired the rights of the ACCUM technology in 2020. On May 7, 2021, the Company’s common shares were listed on the Canadian Securities Exchange (“CSE”) and began trading under the symbol “DTC”. Defence Therapeutics intends to use the ACCUMTM Technology as a carrier of drugs or biologic compounds to increase their accumulation in target cell’s nucleus such as tumor or virus cells. This enhanced absorption could result in higher treatment efficiency and lower unwanted side effects.

Underlying
DEFENCE THERAPEUTICS INC

Provider
GBC AG
GBC AG

Die GBC AG mit Sitz in Augsburg ist eines der führenden bankenunabhängigen Investmenthäuser in Deutschland und erfahrener Emissionsexperte für den deutschen Mittelstand.

Die GBC AG kennt als eigentümergeführtes Unternehmen die Bedürfnisse des deutschen Mittelstandes im Finanzierungsbereich und ist ein unabhängiger und verlässlicher Partner bei allen Fragestellungen rund um den Kapitalmarkt.

In der GBC Gruppe bietet die GBC AG Unternehmensanalysen & Research, Kapitalmarkt- & Finanzierungsberatungen sowie Kapitalmarktkonferenzen.

Die GBC Kapital GmbH ergänzt die Leistungen in der Gruppe um das Corporate Finance in den Bereichen Platzierung & Vermittlung von Anleihen und Aktien

Analysts
Cosmin Filker

Julien Desrosiers

Other Reports on these Companies
Other Reports from GBC AG

ResearchPool Subscriptions

Get the most out of your insights

Get in touch